Tirzepatide vs Semaglutide: Which One Works Better for Weight Loss?

The core difference is that tirzepatide activates two gut hormone receptors while semaglutide activates one. Semaglutide (sold as Ozempic and Wegovy) is a GLP-1 receptor agonist, mimicking a hormone that curbs appetite and slows stomach emptying. Tirzepatide (sold as Mounjaro and Zepbound) is a dual GIP and GLP-1 receptor agonist, meaning it also mimics a second hormone, glucose-dependent insulinotropic polypeptide (GIP), which appears to improve how the body handles fat and blood sugar. Both are once-weekly injections, both were first approved for type 2 diabetes and later for obesity, and both work by reducing hunger and 'food noise.' The two-hormone approach of tirzepatide is the leading theory for why it tends to produce slightly more weight loss in studies. If you want a deeper look at the underlying biology, see how GLP-1 medications work.

Tirzepatide produced more weight loss than semaglutide in the first direct head-to-head trial. In SURMOUNT-5 (NEJM 2025), adults with obesity but without diabetes lost about 20.2% of body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks, a relative difference of roughly 47%. These results line up with the separate landmark trials: in SURMOUNT-1 (NEJM 2022), the highest tirzepatide dose delivered up to 20.9% average weight loss, while STEP 1 (NEJM 2021) showed about 14.9% for semaglutide. It is important to read these as averages, not guarantees: many people on semaglutide lose more than the average, and some on tirzepatide lose less. Response varies with dose, adherence, nutrition, and individual biology. For most people the practical takeaway is that both drugs are far more effective than older weight-loss medications, with tirzepatide holding a measurable edge on the scale.

The side effect profiles of tirzepatide and semaglutide are broadly similar, with gastrointestinal symptoms leading the list for both. The most common are nausea, diarrhea, constipation, and vomiting, which tend to be mild to moderate and ease as your body adjusts over the first weeks. In SURMOUNT-5, rates of these gut side effects were comparable between the two drugs, and serious side effects were uncommon. Both carry a boxed warning about a rare risk of thyroid C-cell tumors seen in rodents and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Slow dose increases (titration) reduce side effects for either medication. Managing common issues like constipation and bloating early makes both far more tolerable. If side effects are intolerable on one drug, some people do better switching to the other, which is a conversation to have with your prescriber.

Choose based on your goals, tolerability, heart-health needs, insurance, and cost, not the headline percentage alone. If maximum weight loss is the priority and you tolerate it, tirzepatide has the statistical edge. If you have established cardiovascular disease, semaglutide as Wegovy has proven reduction in major heart events in the SELECT trial (NEJM 2023), a unique advantage today. Coverage and price often decide the matter: formularies, manufacturer savings cards, and supply can all push you toward one option. Some people start on whichever their insurance covers and switch later. Delivery format may matter too, since an oral semaglutide option exists for those who dislike injections, though it is less potent than the injectables. The best medication is the one you can afford, tolerate, and take consistently. A provider can match the drug to your full health picture, and Lea can help you organize the questions to ask.